Recommended

New webinar: The path to optimisation in pharmaceutical microbiology
New webinar in 2025: Trends for life sciences quality leaders in 2025 – mastering what matters! Register your details now to secure your place!
New upcoming webinar: Navigating pharmaceutical environmental monitoring in a changing industry! Register your details today!
Explore our new Pharma Horizons: Sustainability report for key developments in the pharmaceutical industry!
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
news

Safety warnings for opioid medicines in UK to be added to labels

Warnings about addiction will be added to the patient information leaflets of opioids, the MHRA has announced.

White opioids in bottle

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced that additional warnings are now to be added to the patient information leaflet of opioid medicines. The move is to reinforce safety warnings, making it clear that the medicine is an opioid and can cause addiction. The leaflets will also warn patients that there can be withdrawal symptoms if they stop taking their medication suddenly. According to the MHRA, more information and warnings are to be provided throughout the leaflet.

The agency also says that patients who take prescribed or over-the-counter opioids for non-cancer pain will now be given stronger warnings about the risk of dependence and addiction.

Minister for Innovation Lord James Bethell said: “It is vital that patients are given the right support and guidance on the dangers of long term use and the strengthening of these labels is a crucial step forwards in protecting patients and saving lives.”

The MHRA Director of Vigilance and Risk Management of Medicines, Sarah Branch said: “Last year, we announced that opioid-containing medicine packaging must carry warnings. Now, we are strengthening those warnings to ensure that opioid medicines are supplied with consistent information on how to manage the risk of addiction. This is a further step forward in helping to promote the safe use of these pain-relieving medicines.” 

Following concerns raised about the prescribing rates of opioids in the UK, the Opioid Expert Working Group (EWG) of the Commission on Human Medicines (CHM) developed a set of recommendations to improve information for prescribers and patients and to protect public health. These recommendations were fully supported by CHM and formed the basis of the MHRA’s new warnings.

While the CHM continues to consider opioids as important and effective medicines in the treatment of short-term pain relief, they have advised against their long-term use in the treatment of non-cancer pain, due to the risk of dependence and addiction.